Clinical Trial

A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study consists of a Dose-Escalation stage and a Dose Expansion stage. The primary purpose of the dose escalation stage is to determine the maximum tolerated dose (MTD) and/or recommended dosage(s) for expansion (RDE\[s\]); and the dose expansion stage is to evaluate the preliminary antitumor activity of XB628 as a single agent and in combination with zanzalintinib.
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-06-25
notable Enrollment increased: 75 -> 303 participants 2026-06-25
minor Trial arms changed: 1 -> 2 2026-06-25
notable Primary completion pushed: 2027-05 -> 2027-05-31 2026-05-15
Trial Details
NCT Number NCT06952010
Lead Sponsor Exelixis
Conditions Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Immune Sensitive Tumor
Enrollment 303 participants
Start Date 2025-05-01
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-24